1. Home
  2. PTHL vs XTNT Comparison

PTHL vs XTNT Comparison

Compare PTHL & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTHL
  • XTNT
  • Stock Information
  • Founded
  • PTHL 1998
  • XTNT N/A
  • Country
  • PTHL China
  • XTNT United States
  • Employees
  • PTHL N/A
  • XTNT N/A
  • Industry
  • PTHL
  • XTNT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PTHL
  • XTNT Health Care
  • Exchange
  • PTHL Nasdaq
  • XTNT Nasdaq
  • Market Cap
  • PTHL 65.0M
  • XTNT 74.1M
  • IPO Year
  • PTHL 2024
  • XTNT N/A
  • Fundamental
  • Price
  • PTHL $4.35
  • XTNT $0.43
  • Analyst Decision
  • PTHL
  • XTNT Strong Buy
  • Analyst Count
  • PTHL 0
  • XTNT 1
  • Target Price
  • PTHL N/A
  • XTNT $3.00
  • AVG Volume (30 Days)
  • PTHL 150.0K
  • XTNT 82.6K
  • Earning Date
  • PTHL 11-26-2024
  • XTNT 11-12-2024
  • Dividend Yield
  • PTHL N/A
  • XTNT N/A
  • EPS Growth
  • PTHL N/A
  • XTNT N/A
  • EPS
  • PTHL N/A
  • XTNT N/A
  • Revenue
  • PTHL $572,291.00
  • XTNT $113,862,000.00
  • Revenue This Year
  • PTHL N/A
  • XTNT $31.82
  • Revenue Next Year
  • PTHL N/A
  • XTNT $13.64
  • P/E Ratio
  • PTHL N/A
  • XTNT N/A
  • Revenue Growth
  • PTHL 2.32
  • XTNT 45.11
  • 52 Week Low
  • PTHL $3.32
  • XTNT $0.43
  • 52 Week High
  • PTHL $6.45
  • XTNT $1.45
  • Technical
  • Relative Strength Index (RSI)
  • PTHL N/A
  • XTNT 23.88
  • Support Level
  • PTHL N/A
  • XTNT $0.61
  • Resistance Level
  • PTHL N/A
  • XTNT $0.54
  • Average True Range (ATR)
  • PTHL 0.00
  • XTNT 0.03
  • MACD
  • PTHL 0.00
  • XTNT -0.01
  • Stochastic Oscillator
  • PTHL 0.00
  • XTNT 0.00

About PTHL Pheton Holdings Ltd Class A Ordinary Shares

Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

About XTNT Xtant Medical Holdings Inc.

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Share on Social Networks: